Liposomal Chemotherapy Market Report 2026

The liposomal chemotherapy market size has grown strongly in recent years. It will grow from $3.11 billion in 2025 to $3.39 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to high toxicity of conventional chemotherapy treatments, limited tumor targeting efficiency in traditional drug delivery, increasing cancer prevalence and treatment demand, development of first generation liposomal drug formulations, growing adoption of hospital based chemotherapy infusion therapies.

The liposomal chemotherapy market size is expected to see strong growth in the next few years. It will grow to $4.87 billion by 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to expansion of personalized oncology and precision medicine approaches, increasing adoption of targeted and reduced toxicity chemotherapy systems, growth in nanotechnology based drug delivery innovations, rising clinical trials for advanced liposomal formulations, increasing integration of biomarker driven cancer therapy selection. Major trends in the forecast period include precision nanocarrier based drug delivery optimization, targeted tumor microenvironment drug accumulation enhancement, long circulating stealth liposome formulation advancements, combination therapy integration with liposomal chemotherapy, biomarker guided personalized oncology treatment strategies.

The rising demand for targeted drug delivery systems is expected to propel the growth of the liposomal chemotherapy market going forward. Targeted drug delivery systems are advanced formulations designed to transport therapeutic agents directly to diseased tissues while minimizing exposure to healthy cells, thereby improving treatment precision and reducing systemic toxicity. The increasing demand for targeted drug delivery systems is driven by the growing need to reduce side effects by delivering medicines precisely to affected cells while sparing healthy tissues. Liposomal chemotherapy supports this demand by encapsulating anticancer drugs within lipid vesicles, enabling controlled release and preferential accumulation at tumor sites, thereby enhancing safety and treatment outcomes. For instance, in July 2024, according to the National Library of Medicine (NLM), a US-based biomedical library, prescription drug spending is projected to increase by 10%-12% in 2024 compared to 2023. Therefore, the rising demand for targeted drug delivery systems is contributing to and propelling the growth of the liposomal chemotherapy market.

Leading companies operating in the liposomal chemotherapy market are focusing on advancements in liposome formulation, such as next-generation liposomal drug delivery platforms that enhance targeted delivery and controlled release of anticancer agents. Next-generation liposomal drug delivery platforms are proprietary liposomal systems engineered to improve drug stability, extend circulation time, and preferentially accumulate at tumor sites, increasing therapeutic efficacy while reducing systemic toxicity. For example, in August 2024, Lupin Limited, an India-based pharmaceutical company, launched Doxorubicin Hydrochloride Liposome Injection in single-dose vial formulations. The product enables improved delivery of the drug to cancer cells, supports controlled release, and offers flexibility through multiple vial strengths for optimized dosing. Additionally, the launch aligns with increasing demand for safer and more precise chemotherapy options, strengthening Lupin’s oncology portfolio and expanding access to advanced liposomal treatments in the market.

In January 2024, CHEPLAPHARM, a Germany-based pharmaceutical company, acquired the European commercial rights to Myocet from Teva Pharmaceutical Industries Ltd for an undisclosed amount. Through this acquisition, CHEPLAPHARM strengthened its oncology portfolio, expanded its presence in the targeted drug delivery segment, and improved market access for its liposomal chemotherapy offerings in Europe. Teva Pharmaceutical Industries Ltd is an Israel-based pharmaceutical company with an established presence in liposomal chemotherapy treatments, offering oncology products that utilize advanced drug delivery technologies to enhance therapeutic outcomes.

Major companies operating in the liposomal chemotherapy market are Johnson & Johnson Services Inc., Merck & Co. Inc., Pfizer Inc., Sanofi SA, Novartis AG, GSK plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Astellas Pharma Inc., CSPC Pharmaceutical Group Limited, Jazz Pharmaceuticals plc, Sichuan Kelun Pharmaceutical Co. Ltd., Cipla Inc., Hikma Pharmaceuticals PLC, Cadila Pharmaceuticals Ltd., Lupin Limited, Zydus Lifesciences Ltd., Towa Pharmaceutical Co. Ltd., CHEPLAPHARM Arzneimittel GmbH, Luye Pharma Group Ltd., TTY Biopharm Company Limited, Accord Healthcare Limited, SRS Life Sciences, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd.

North America was the largest region in the liposomal chemotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liposomal chemotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the liposomal chemotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The liposomal chemotherapy market consists of sales of liposomal doxorubicin, liposomal paclitaxel, liposomal irinotecan, liposomal daunorubicin, liposomal cytarabine, liposomal vincristine, liposomal mitoxantrone, and liposomal amphotericin B. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.